BIO-TISSUE

Redefining the Standard of Care: A Consensus Guideline: If you want to stay ahead of the curve in managing cornea-involved ocular surface disease, then you don’t want to miss this webinar featuring Drs. Marguerite McDonald, Neel Desai, Clifford Salinger, Mark Milner and John Sheppard. These five renowned experts highlight their recommendations for the use of cryopreserved amniotic membrane in the following indications: persistent epithelial defect, corneal ulcer/infectious keratitis, recurrent corneal erosion, severe dry eye disease, epithelial basement membrane dystrophy, neurotrophic keratitis and optimizing the ocular surface prior to refractive cataract surgery. Access the webinar by registering for our Physician’s Portal.
tinyurl.com/VEC20BioTissue

BVI

In this on-demand video, Elizabeth Yeu, MD, discusses “Surgical Efficiency with the First and Only Preloaded Monofocal Available in Both a 1-Piece and 3-Piece Design.”
tinyurl.com/VEC20BVI

COMPULINK

At Compulink, we have spent a lot of time preparing for the upcoming 2021 E/M coding changes. The last time the E/M coding underwent this major a revision was in the 1990s. These changes will have a huge impact on workflow and payment eligibility for providers. We’ve consulted with industry coding experts to help ensure providers will get paid the maximum amount for their services and that we’re ready by the January deadline.

Our Advantage SMART Practice, all-in-one database solution includes an ophthalmology specific EHR, practice management, inventory management, patient engagement, ASC, E-commerce and Optical POS. The company also provides an expert revenue cycle management service for its clients.

To learn more, visit the link below, and ask about our 2021 E/M guarantee.
https://www.compulinkadvantage.com/videos/

GLAUKOS

At Glaukos, we are dedicated to addressing the greatest unmet needs of the global ophthalmic market, for physicians and for patients. That’s why we’ve spent more than a decade re-investing in R&D and clinical trial programs to develop and advance an extensive pipeline of novel therapies currently being evaluated in FDA clinical trials, while leading the industry in clinical support and patient education resources. And it’s why we’re seeking to leverage our platform technologies to build a portfolio of next-generation surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease. We’ve achieved many firsts in clinical studies, and continue to reinvest 27% of net sales exclusively on research and development efforts — all to relentlessly advance our goal of creating and delivering transformative therapies for patients struggling with eye diseases and the skilled surgeons dedicated to their healing.
www.glaukos.com

GUARDION HEALTH SERVICES

Guardian Health Sciences Inc. is a specialty health sciences company that develops medical foods and medical devices to maximize ocular health. Nutriguard, a Guardion Health Sciences company, markets industry-leading medical foods like Lumega-Z, which replenishes and restores the macular pigment, including in patients with AMD, and GlaucoCetin, created to offset mitochondrial dysfunction in the optic nerve cells of glaucoma patients. Lumega-Z is a micronized, lipid-based liquid formula that contains the essential macular carotenoids of lutein, zeaxanthin and meso-zeaxanthin, the super antioxidant astaxanthin, along with other potent anti-inflammatory and antioxidant ingredients. GlaucoCetin contains a range of natural neuroprotective ingredients, Ginkgo biloba to support vascular function and a potent combination of anti-inflammatory and antioxidant natural agents. VectorVision, a Guardion Health Sciences company, offers sophisticated and sensitive medical devices, which are used to track, after treatment, recovery or changes in vision using contrast sensitivity (CSV-1000 and CSV-2000), and the restoration of the macular pigment optical density (MapCatSF). The synergy of these two product lines provides evidence-based protocols to enable clinicians to better measure and evaluate the success of treatment with Nutriguard medical foods and to support improved patient compliance. Learn more at the link below.
lumegaz.com/value-proposition

HAAG-STREIT

Join our expert panel of ophthalmologists for a casual and informative happy hour on Nov. 17, 2020 at 8 p.m. EST to discuss practice changes made due to COVID-19. This webinar, “Eye Care and COVID-19: Do They Mix?,” will explore the modifications made to practice workflow to better protect doctors, staff and patients during this pandemic. Our panel will provide insights from several different specialty perspectives: cornea/cataract, glaucoma and retina.

Grab your favorite beverage and bring your questions. We hope to see you at happy hour!
tinyurl.com/VEC20HaagStreit

HEIDELBERG

Confocal scanning laser ophthalmoscopy (cSLO) provides high contrast, high quality images, even in challenging patients. Watch the informative “Harnessing the Power of cSLO with SPECTRALIS” webinar to gain deeper understanding of cSLO imaging technology and imaging modalities available on Heidelberg Engineering’s SPECTRALIS. Modalities reviewed include IR, BluePeak Autofluorescence, MultiColor, FA and ICGA.
tinyurl.com/VEC20Heidelberg

IMPRIMISRX

This white paper serves as a primer for surgeons on compounding pharmacies and compounded medications. Under the 2013 Drug Quality and Security Act (DQSA), enacted to improve drug supply chain security and to give the FDA more regulatory authority, two types of compounding pharmacies were established — 503A and 503B. Lee H. Rosebush, JD, chairman of the Outsourcing Facilities Association (OFA), explains the differences in the designations, including intended use of medication, regulatory bodies and standards, reporting and inspection.

William Wiley, MD, discusses the important role that compounded medications play in ophthalmology, including compliance benefits, patient convenience and cost savings. Dr. Wiley addresses frequently asked questions about the quality and legality of compounded pharmaceuticals and provides 10 questions that clinicians should ask when choosing a compounding pharmacy. Registration as an FDA-registered 503B outsourcing facility, such as ImprimisRx, is shown to be a clear indication of high-quality manufacturing standards and federal oversight for compounded medications. Please follow the link below to read the white paper in its entirety.
www.imprimisrx.com/primer

LENSAR

LENSAR, the leader in next-generation femtosecond cataract laser technology, continues to focus on astigmatism with Streamline IV. This includes numerous features unique to the LENSAR Laser that are dedicated to help surgeons confidently manage astigmatism and optimize patient outcomes, for both toric IOLs and arcuate incisions.

Enhancements include IntelliAxis Refractive Capsulorhexis, which incorporates steep axis capsular markings that guide precise toric IOL alignment, and wireless transfer of preoperative diagnostics from multiple preop diagnostic devices for seamless treatment planning. Iris registration further contributes to the system’s accuracy by automatically accounting for cyclotorsion.

A summary of Streamline IV data can be found in the following peer-review article: tinyurl.com/VEC20LENSAR1 . Also, learn more about what surgeons say about the LENSAR laser system by viewing a webinar featuring Burkhard Dick, MD, PhD, and Robert Weinstock, MD (tinyurl.com/VEC20LENSAR2 ) or visiting the link below for several surgeon testimonials.
evolved.lensar.com

NIDEK

Nidek offers a wide array of equipment designed for the diagnosis and treatment of retinal diseases, glaucoma and other vision-impairing afflictions. With over 45 years of experience in this industry, we strive to continue pushing the boundaries as innovators. Our pledge to excellence will move us forward in answering the needs of vision-care providers throughout the world.

Recently, Nidek launched the advanced YC-200 S plus YAG/SLT combination laser, which is the successor to the YC-1800 laser. The YC-200 S plus laser builds on the popularity and technology of the YC-1800 by incorporating newer optical designs, engineering and software advances to ensure precise targeting of pathology, while ensuring efficacious treatments and enhancing surgeon visualization of laser delivery.

To learn more about how the YC-200 S plus is delivering treatments right on the mark, follow the link below to a product spotlight column. For more info, please contact us at info@nidek.com.
bit.ly/39jxTnV

NOTAL VISION

Remote patient monitoring is fast becoming an essential tool to help physicians extend eye disease management from the clinic to the home. Learn why protecting at-risk dry AMD patients through home diagnostics and remote monitoring is so important. Paul Karpecki, OD, and John Kitchens, MD, discuss the unmet needs of the intermediate AMD population, the importance of detecting wet AMD early and the impact of severe vision loss on patients' lives.
tinyurl.com/VEC20NotalVision

QUANTEL

Consider selective laser trabeculoplasty (SLT) first for glaucoma patients: SLT therapy is non-destructive laser therapy that can be used as a primary treatment option and can be used in combination with drug therapy or as an alternative therapy when drugs fail. SLT has a very short pulse duration (4 ns), which is shorter than the thermal relaxation time of melanin, allowing for selective photothermolysis. Because SLT selectively targets the pigmented trabecular meshwork (TM) cells and has an energy level 1% of argon laser trabeculoplasty (ALT), it is a gentler laser than ALT with no histologic scarring or coagulative damage to the TM. It thus reduces collateral damage to surrounding tissues and makes repeat treatments possible. To learn more, visit the link below.
tinyurl.com/VEC20Quantel

SANTEN

Advancing ophthalmic solutions for the benefit of patients. When a patient’s vision is threatened, they look to their ophthalmologist for a brighter future. Preserving eyesight while enhancing the patient experience is our singular focus. That’s why Santen is dedicated to finding innovative solutions in corneal disorders, dry eye, glaucoma and retinal diseases, so that ophthalmologists can help their patients enjoy eyesight for longer.

In addition, Santen announced a new long-term vision for the company’s future as it celebrate its 130th anniversary. The corporate slogan has been updated to “Imagine Your Happiness” to better reflect Santen’s aspiration not simply to make functional improvements in eyesight, but also to improve experience value and contribute to society, thereby achieving happiness for everyone by focusing on vision.

Learn more about how Santen is innovating across all of ophthalmology.
www.SantenVirtual.com